Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsIndependent Health Step Therapy Coverage Update | …
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentIndependent HealthPolicy N/A

    Step Therapy Criteria for Medicare Part B Drugs

    Customize your policy alerts

    Sign up for all Independent Health policy alerts

    Know when Independent Health releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines step therapy (prior-authorization) requirements for specific Medicare Part B drugs under Independent Health Medicare Advantage plans for 2026; applies to new therapy starts and describes required prior treatments or failures before coverage is approved.

    Policy Summary
    PayerIndependent Health
    PolicyStep Therapy Criteria for Medicare Part B Drugs (coverage criteria)
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateJan 1, 2026
    Next Review DateN/A
    Key ActionDocument prior trial and inadequate response, intolerance, or contraindication to the specified preferred agent(s) for new starts.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    50pages
    5/1/2026current as of
    new-starts onlyapplies to
    ~150listed products
    4 monthspaliperidone prior tx

    Coverage Criteria

    Zilretta

    Covered when ALL of the following are met for new starts:

    The patient must have tried and failed to have an adequate response to at least one other injectable corticosteroid.
    This requirement applies to new starts only.

    Provider Actions and Documentation

    Prior Authorization

    Require prior bevacizumab trial (Avastin) for new starts

    For new therapy starts, prior authorization requires documentation that the patient tried and failed to have an adequate response to bevacizumab (Avastin).

    • Applies to specified ophthalmic agents (new starts only).
    Policy Summary
    PayerIndependent Health
    PolicyStep Therapy Criteria for Medicare Part B Drugs (coverage criteria)
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateJan 1, 2026
    Next Review DateN/A
    Key ActionDocument prior trial and inadequate response, intolerance, or contraindication to the specified preferred agent(s) for new starts.
    SourceLink
    On This Page
    Coverage CriteriaProvider Actions and DocumentationCoding and BillingInitial Therapy (New Starts) CriteriaStep Therapy Summary TableSite of Care and BillingBiosimilar and Comparator RequirementsDefinitionsBackground
    Prior Authorization

    Document trial and failure of Onpattro before AMVUTTRA

    Prior authorization for AMVUTTRA new starts requires documentation that the patient tried and failed to have an adequate response to Onpattro.

    • This requirement applies to new starts only.
    Prior Authorization

    Require prior plerixafor trial for APHEXDA

    Prior authorization for APHEXDA new starts requires documentation that the patient tried and failed to have an adequate response to plerixafor.

    • This requirement applies to new starts only.
    Prior Authorization

    Document trial and failure of another IVIG before Asceniv

    For Asceniv new starts (shared indications), prior authorization requires documentation that the patient tried and failed to have a response to another IVIG product.

    • Does not apply when Asceniv is used for an indication not shared with preferred IVIG products.
    Prior Authorization

    Require trial of Mvasi or Zirabev before certain bevacizumab agents

    Prior authorization for listed oncology bevacizumab agents requires evidence that the patient tried and had an inadequate response to the preferred bevacizumab biosimilars Mvasi or Zirabev.

    • Applies to Alymsys, Avastin (oncology), Jobevne, or Vegzelma for oncology indications (new starts only).
    • Does not apply to ophthalmic Avastin uses or indications not shared with Mvasi/Zirabev.
    Prior Authorization

    Document trial and inadequate response to specified denosumab biosimilars

    Prior authorization for Prolia, Xgeva, or non-preferred denosumab biosimilars on new starts requires documentation that the patient tried and failed to have an adequate response to the specified preferred denosumab biosimilars.

    • For Prolia/non-preferred Prolia biosimilars: trial and failure of Bildyos or Jubbonti required.
    • For Xgeva/non-preferred Xgeva biosimilars: trial and failure of Bilprevda or Wyost required.
    • Does not apply when indication is not shared with the preferred biosimilars.
    Prior Authorization

    Require documented trial of Ruxience or Riabni before rituximab products

    Prior authorization for listed rituximab-affected products on new starts requires documentation that the patient tried and failed to have an adequate response to Ruxience, Riabni, or another rituximab product.

    • Failure to document prior trial and inadequate response may trigger denial.
    Prior Authorization

    Document trial and failure of Retacrit for epoetin alfa alternatives

    Prior authorization for epoetin alfa alternatives on new starts requires documentation that the patient tried and failed to have an adequate response to Retacrit.

    • Does not apply to patients using Epogen or Procrit for indications not shared with Retacrit.
    Prior Authorization

    Require Zarxio trial and inadequate response for G‑CSF products

    Prior authorization for listed granulocyte‑colony stimulating factor products on new starts requires documentation that the patient tried and failed to have an adequate response to Zarxio.

    • Does not apply when the patient is using a non-preferred agent for an indication not shared with Zarxio.
    Documentation Required

    Document required prior paliperidone palmitate treatment for Invega Hafyera

    Prior authorization for Invega Hafyera new starts requires proof of prior paliperidone palmitate extended‑release treatment as specified (≥4 months of 1‑month formulation or at least one 3‑month injection).

    • Documentation must show duration and formulation of prior paliperidone palmitate treatment.
    • Lack of such documentation may trigger denial.
    Documentation Required

    Document ≥4 months' 1‑month paliperidone palmitate before Invega Trinza

    Prior authorization for Invega Trinza new starts requires documentation of at least 4 months' treatment with 1‑month paliperidone palmitate extended‑release injectable suspension.

    • Absence of this documentation may trigger denial.
    Prior Authorization

    Require trial and failure of generic leucovorin before Khapzory

    Prior authorization for Khapzory new starts requires documentation that the patient tried and failed to have an adequate response to generic leucovorin.

    • Does not apply when the patient is using levoleucovorin for indications not shared with leucovorin.
    Prior Authorization

    Document Jivi failure for hemophilia factor product approvals

    Prior authorization for Adynovate, Eloctate, or Esperoct new starts requires documentation that the patient tried and failed to have an adequate response to Jivi.

    • Records indicating prior use and inadequate response to Jivi are required; absence may cause denial.
    Prior Authorization

    Require Tyruko trial and failure before Tysabri

    Prior authorization for Tysabri new starts requires documentation that the patient tried and failed to have an adequate response to Tyruko (natalizumab‑sztn).

    • Does not apply when the requested indication differs from Tyruko's.
    Prior Authorization

    Document Opdivo+Yervoy failure or Yervoy contraindication for Opdualag

    Prior authorization for Opdualag new starts requires documentation of prior failure of Opdivo plus Yervoy, or a documented contraindication to Yervoy.

    • Lack of trial or documented contraindication may cause denial.
    Prior Authorization

    Require generic paclitaxel trial before Abraxane (non‑pancreatic indications)

    Prior authorization for Abraxane (for indications other than pancreatic cancer or small bowel carcinoma) requires documentation that the patient tried and failed to have an adequate response to generic paclitaxel.

    • Does not apply when Abraxane is used for an indication not shared with generic paclitaxel.
    Prior Authorization

    Require Udenyca trial and failure before non‑preferred pegfilgrastim biosimilars/Ryzneuta

    Prior authorization for non‑preferred pegfilgrastim biosimilars or Ryzneuta new starts requires documentation that the patient tried and failed to have an adequate response to Udenyca.

    • Does not apply when indication is not shared with the preferred pegfilgrastim product.
    Prior Authorization

    Require prior pemetrexed trial for Axtle/Pemfexy/Pemrydi new starts

    Prior authorization for Axtle (J9292), Pemfexy (J9304), or Pemrydi (J9324) new starts requires documentation that the patient tried and failed to have an adequate response to an allowed pemetrexed product (listed pemetrexed HCPCS codes), unless contraindicated or not tolerated.

    • Requests will be denied if prior trial and failure of pemetrexed (listed HCPCS) are not documented for new starts (unless contraindicated or not tolerated).
    Prior Authorization

    Document pemetrexed trial and failure for Axtle/Pemfexy/Pemrydi RTU

    For Axtle, Pemfexy, or Pemrydi RTU new starts, prior authorization requires documentation that the patient tried and failed pemetrexed (listed pemetrexed HCPCS codes) unless contraindicated or not tolerated.

    • Absence of documented pemetrexed trial and failure may result in denial.
    Step Therapy

    Intravitreal anti‑VEGF prior trial of bevacizumab (and second‑step when specified)

    Prior authorization for intravitreal ranibizumab products or other listed intravitreal anti‑VEGF agents on new starts requires documentation that the patient tried and failed bevacizumab (Avastin); for certain agents an additional second‑step trial is required as specified.

    • Step 1: bevacizumab (Avastin).
    • Step 2 (for some agents): either Cimerli/ranibizumab‑eqrn or aflibercept, brolucizumab, or faricimab as specified for Byooviz, Lucentis, Susvimo (new starts only).
    Billing Rule

    Medical prior authorization required for viscosupplements (billable to Medicare Part B)

    Medical prior authorization is required for all viscosupplements; because they are medical devices they must be billed through Medicare Part B.

    • For non‑preferred viscosupplements, documentation of trial and failure or intolerance to both preferred agents (Euflexxa and Synvisc‑One) is required for new starts.
    Note

    Index entries—cross‑reference individual drug policies for PA rules

    This index lists drugs alphabetically and does not itself specify prior authorization or step therapy rules; providers must cross‑reference the individual drug policy sections for the applicable PA rules.

    • Use the product‑specific policy sections for submission and PA requirements.
    Step Therapy

    Require bevacizumab (Avastin) trial before EYLEA/BEOVU for certain ophthalmic indications

    For new ophthalmic angiogenesis inhibitor starts (EYLEA, BEOVU), prior authorization requires documentation that the patient tried and failed to have an adequate response to bevacizumab (Avastin) for the specified indications.

    • Applies to neovascular AMD, diabetic macular edema, and other specified ophthalmic indications (new starts only).
    Step Therapy

    Require IV gemcitabine trial before Avgemsi (shared oncology indications)

    For Avgemsi new oncology starts, prior authorization requires documentation that the patient tried and failed to have an adequate response to intravenous gemcitabine for shared indications.

    • Does not apply to indications not shared with gemcitabine.
    Step Therapy

    Require Treanda (J9033) trial before Belrapzo/bendamustine products

    For Belrapzo and other bendamustine products, new starts require documentation that the patient tried and failed to have an adequate response to Treanda (J9033) unless contraindicated or not tolerated.

    • Does not apply to indications not shared with Treanda.
    Step Therapy

    Require Mvasi or Zirabev trial before certain oncology bevacizumab agents

    For Alymsys, Avastin (oncology), Jobevne, or Vegzelma new oncology starts, prior authorization requires documentation that the patient tried and failed to have an adequate response to Mvasi or Zirabev.

    • Exemptions: ophthalmic Avastin uses and indications not shared with Mvasi/Zirabev.
    Step Therapy

    Require emtricitabine/tenofovir intolerance or contraindication for Apretude

    Apretude approval requires that the patient tried and had an intolerance to or has a contraindication to emtricitabine/tenofovir disoproxil fumarate prior to approval.

    • This is a prerequisite for new starts.
    Step Therapy

    Document failure of Botox and Xeomin before Myobloc

    For Myobloc new starts, prior authorization requires documentation that the patient tried and failed to have an adequate response to both Botox and Xeomin.

    • Applies to new starts only.
    Step Therapy

    Require Ocrevus trial and failure before Briumvi

    For Briumvi new starts, prior authorization requires documentation that the patient tried and failed to have an adequate response to Ocrevus.

    • Applies to new starts only.
    Step Therapy

    Require trial and failure of Eligard/Lupron or carboplatin as specified

    For Camcevi new starts, prior authorization requires documentation that the patient tried and failed to have an adequate response to Eligard (and for Kyxata the comparator is carboplatin); applies only when indications are shared with the comparator.

    • Does not apply when the requested indication is not shared by the comparator.
    Step Therapy

    Document prior biologic trial/failure for NMOSD and gMG biologics

    For NMOSD and generalized myasthenia gravis new starts, prior authorization requires documentation of trial and failure, intolerance, or contraindication to the listed prior biologics (e.g., Enspryng and either Uplizna or rituximab for NMOSD; Vyvgart or Vyvgart Hytrulo for gMG).

    • Documentation of prior trial/intolerance/contraindication is required for approval.
    Step Therapy

    Require Ruxience or Riabni trial before Enjaymo

    For Enjaymo new starts, prior authorization requires documentation that the patient tried and failed to have an adequate response to Ruxience or Riabni (or another rituximab product).

    • Applies to new starts only.
    Step Therapy

    Document statin and PCSK9 inhibitor trial/contraindication for Evkeeza

    For Evkeeza new starts, prior authorization requires documentation that the patient tried and failed to have an adequate response to or has a contraindication to both a maximally‑tolerated statin and a PCSK9 inhibitor.

    • Failure to document these prior therapies may trigger denial.
    Step Therapy

    Require Hemlibra failure before Feiba

    For Feiba new starts, prior authorization requires documentation that the patient tried and failed to have an adequate response to Hemlibra.

    • Does not apply to treatment of hemophilia B.
    Step Therapy

    Require Cosentyx + one additional biologic trial for Ilumya

    For Ilumya new starts, prior authorization requires documentation that the patient tried and failed to have an adequate response to the formulary‑preferred IL‑17 inhibitor (Cosentyx) and one listed on‑formulary biologic or infliximab/Remicade.

    • Documentation of trial and inadequate response or intolerance to the preferred IL‑17 inhibitor and one other listed biologic is required.
    Step Therapy

    Document prior cemiplimab regimen response/intolerance for Imjudo (NSCLC)

    For Imjudo (NSCLC) new starts, prior authorization requires documentation that the patient had an adequate response to or intolerance/contraindication to regimens containing cemiplimab (Libtayo).

    • Applies to the NSCLC indication (new starts only).

    Coding and Billing

    Bendamustine HCPCS (step requirement)HCPCS
    J9036Belrapzo / bendamustine Apotex / Baxter
    J9034Bendeka solution 100 mg/4 mL IV
    J9056Vivimusta solution 100 mg/4 mL IV
    J9033Treanda (comparative agent)
    Oncology J-codes with step requirementHCPCS
    J9172Docivyx
    J9174Beizray
    J9171Docetaxel (step agent)
    Bevacizumab products and biosimilarsHCPCS
    Alymsys, Avastin, Jobevne, Vegzelma (Avastin ophthalmic exceptions apply)
    Mvasi and Zirabev (required step agents for oncology indications)
    J9035Bevacizumab (Avastin) - HCPCS example code (if applicable)
    Erythropoiesis-stimulating agentsmixed
    Products listed: Epogen (various strengths), Procrit (various strengths)
    Pemetrexed and AlternativesHCPCS
    J9292Axtle
    J9304Pemfexy
    J9324Pemrydi RTU
    J9294Pemetrexed (related code)
    J9296Pemetrexed (related code)
    J9297Pemetrexed (related code)
    J9305Pemetrexed (related code)
    J9314Pemetrexed (related code)
    J9322Pemetrexed (related code)
    J9323Pemetrexed (related code)
    Intravitreal anti-VEGF productsHCPCS
    Byooviz 0.5 mg/0.05 mL intravitreal
    Cimerli 0.3 mg/0.05 mL intravitreal
    Cimerli 0.5 mg/0.05 mL intravitreal
    Lucentis 0.3 mg/0.05 mL intravitreal
    Lucentis 0.5 mg/0.05 mL intravitreal
    Susvimo implant/fill 10 mg/0.1 mL intravitreal
    Avastin (bevacizumab) — intravitreal use subject to step rules
    Rituximab ProductsHCPCS
    Rituxan Hycela solution 1400-23400 mg - UT/11.7 mL subcutaneous
    Rituxan Hycela solution 1600-26800 mg - UT/13.4 mL subcutaneous
    Rituxan solution 500 mg/50 mL IV
    Truxima solution 100 mg/10 mL IV
    Truxima solution 500 mg/50 mL IV
    Rystiggo PresentationsHCPCS
    Rystiggo solution 280 mg/2 mL subcutaneous
    Rystiggo solution 420 mg/3 mL subcutaneous
    Rystiggo solution 560 mg/4 mL subcutaneous
    Rystiggo solution 840 mg/6 mL subcutaneous
    Rytelo PresentationsHCPCS
    Rytelo solution reconstituted 188 mg IV
    Rytelo solution reconstituted 47 mg IV
    Spinraza PresentationsHCPCS
    Spinraza solution 12 mg/5 mL intrathecal
    Spinraza solution 28 mg/5 mL intrathecal
    Spinraza solution 50 mg/5 mL intrathecal
    Tezspire PresentationHCPCS
    Tezspire solution prefilled syringe 210 mg/1.91 mL subcutaneous
    Tocilizumab and AlternativesHCPCS
    Actemra solutions 80 mg/4 mL, 200 mg/10 mL, 400 mg/20 mL IV
    Avtozma solutions 80 mg/4 mL, 200 mg/10 mL, 400 mg/20 mL IV
    Tofidence solutions 80 mg/4 mL, 200 mg/10 mL, 400 mg/20 mL IV
    Trastuzumab and BiosimilarsHCPCS
    Herceptin Hylecta solution 600–10000 mg unit/5 mL subcutaneous
    Herceptin solution reconstituted 150 mg IV
    Herzessi solution reconstituted 150 mg and 420 mg IV
    Herzuma solution reconstituted 150 mg and 420 mg IV
    Ogivri solution reconstituted 150 mg and 420 mg IV
    Ontruzant solution reconstituted 150 mg and 420 mg IV
    Kanjinti and Trazimera (preferred comparators)

    Initial Therapy (New Starts) Criteria

    inv-179: Myobloc initial therapy requirement

    Myobloc-initial: Patient tried and failed Botox and Xeominnew starts only

    Required for Myobloc approval

    inv-180: Rituximab biosimilars — New start requirement

    New start requirement

    Rituximab trial: Patient must have tried and failed to have an adequate response to Ruxience or Riabni (or another rituximab product).

    inv-181: Evkeeza — New start requirement

    New start requirement

    Evkeeza prior therapies: Patient must have tried and failed to have an adequate response to or have a contraindication to both a maximally-tolerated statin and a PCSK9 inhibitor.

    inv-182: New start step therapy requirements — Initial therapy (new starts) rules

    Initial therapy (new starts) rules

    Paliperidone products: Invega Hafyera/Trinza new starts require documented prior paliperidone palmitate therapy as specified (e.g., ≥4 months of 1-month injections or ≥1 three-month injection where applicable).

    See product-specific durations/formulations.

    Rescue/adjunct agents: Khapzory requires failure of generic leucovorin unless indication differs; levoleucovorin exception noted.

    Applies to new starts only.

    Hemophilia factors: Adynovate/Eloctate/Esperoct require failure of Jivi for new starts.

    Applies to new starts only.

    Natalizumab: Tysabri requires failure of Tyruko for new starts unless indication differs.

    inv-183: Initial therapy (selected)

    Initial therapy requirements for select agents (new starts only):

    Axtle/Pemfexy/Pemrydi RTU: Trial and failure of pemetrexed required unless contraindicated or not tolerated.

    inv-184: Herceptin initial therapy

    Initial therapy requirements for new starts

    Herceptin group initial: Patient must have tried and failed to have an adequate response to Kanjinti or Trazimera prior to approval of Herceptin, Herceptin Hylecta, or a non-preferred trastuzumab biosimilar.new starts only

    Step Therapy Summary Table

    Drug / ProductRequired prior therapy (new starts)Notes / Exceptions
    EYLEA (aflibercept) / BEOVU (brolucizumab) and other specified intravitreal anti-VEGF agents
    Patient must have tried and failed to have an adequate response to bevacizumab (Avastin).
    Applies to new starts only; does not apply when the requested product is used for an off-label indication not shared with bevacizumab. For some agents a two-step sequence is specified (see policy).
    Drug / ProductRequired prior therapy (new starts)Notes / Exceptions
    AMVUTTRA
    Patient must have tried and failed to have an adequate response to Onpattro.
    Applies to new starts only.
    Drug / ProductRequired prior therapy (new starts)Notes / Exceptions
    APHEXDA
    Patient must have tried and failed to have an adequate response to plerixafor.
    Applies to new starts only.
    Drug / ProductRequired prior therapy (new starts)Notes / Exceptions
    Asceniv (IVIG)
    Patient must have tried and failed to have a response to another IVIG product.
    Applies to new starts only; does not apply when Asceniv is used for an indication not shared with preferred IVIG products.
    Drug / ProductRequired prior therapy (new oncology starts)Notes / Exceptions
    Avgemsi
    Patient must have tried and failed to have an adequate response to intravenous gemcitabine.
    Applies to new oncology starts only; does not apply for indications not shared with gemcitabine.
    Drug / ProductRequired prior therapy (new starts)Notes / Exceptions
    Belrapzo / other bendamustine products
    Patient must have tried and failed to have an adequate response to Treanda (J9033), unless contraindicated or not tolerated.
    Applies to new starts only; does not apply to indications not shared with Treanda.
    Drug / ProductRequired prior therapy (oncology new starts)Notes / Exceptions
    Alymsys / Avastin (oncology) / Jobevne / Vegzelma
    Patient must have tried and failed to have an adequate response to Mvasi or Zirabev.
    Applies to oncology new starts only; does not apply to ophthalmic uses of Avastin or indications not shared with Mvasi/Zirabev.
    Drug / ProductRequired prior condition (new starts)Notes / Exceptions
    Apretude
    Patient must have an intolerance to or a contraindication to emtricitabine/tenofovir disoproxil fumarate.
    Requirement reflects condition for approval; applies to new starts only where specified.
    Drug / ProductRequired prior therapy (oncology new starts)Notes / Exceptions
    Alymsys / Avastin / Jobevne / Vegzelma
    Patient must have tried and had an inadequate response to Mvasi or Zirabev before initiating these oncology bevacizumab agents.
    Applies to new starts only; does not apply to ophthalmic indications or indications not shared with Mvasi/Zirabev.
    Drug / ProductRequired prior therapy (new oncology starts)Notes / Exceptions
    Docivyx (J9172) / Beizray (J9174)
    Patient must have tried and failed to have an adequate response to docetaxel (J9171).
    Applies to new oncology starts only.
    Drug / ProductRequired prior therapy (new starts)Notes / Exceptions
    Prolia / Xgeva / non-preferred denosumab biosimilars
    For Prolia: patient must have tried and failed Bildyos or Jubbonti. For Xgeva: patient must have tried and failed Bilprevda or Wyost.
    Applies to new starts only; does not apply when the non-preferred denosumab is used for an indication not shared with the specified preferred biosimilars.
    Condition / Drug groupRequired prior therapy (new starts)Notes / Exceptions
    Neuromyelitis optica spectrum disorder (NMOSD)
    Patient must have tried and failed or had intolerance/contraindication to Enspryng and either Uplizna or rituximab.
    Applies to NMOSD new starts only; required prior therapies are enumerated in policy.
    Drug / ProductRequired prior therapy (new starts)Notes / Exceptions
    Enjaymo
    Patient must have tried and failed to have an adequate response to Ruxience or Riabni (or another rituximab product).
    Applies to new starts only.
    Drug group / ProductRequired prior therapy (new starts)Notes / Exceptions
    Rituximab-containing products (Ruxience / Riabni preferred)
    Patient must have tried and failed to have an adequate response to Ruxience or Riabni (or another rituximab product).
    Applies to new starts only; step does not apply when indication is not shared with the preferred rituximab products.
    Drug / ProductRequired prior therapy (new starts)Notes / Exceptions
    Epoetin alfa alternatives (Epogen / Procrit alternatives)
    Patient must have tried and failed to have an adequate response to Retacrit.
    Applies to new starts only; does not apply when Epogen/Procrit are used for indications not shared with Retacrit.
    Drug group / ProductRequired prior therapy (new starts)Notes / Exceptions
    G-CSF products (Filkri, Granix, Neupogen, Nivestym, Nypozi, Releuko)
    Patient must have tried and failed to have an adequate response to Zarxio.
    Applies to new starts only; does not apply when the non-preferred agent is used for an indication not shared with Zarxio.
    Drug / ProductRequired prior therapy (new starts)Notes / Exceptions
    Invega Hafyera (paliperidone palmitate long-acting injectable)
    Documentation of at least 4 months' treatment with 1-month paliperidone palmitate extended‑release injectable suspension OR at least one 3‑month injection of 3‑month paliperidone palmitate is required.
    This documentation is required for new starts only; policy specifies duration/formulation details.
    Drug / ProductRequired prior therapy (new starts)Notes / Exceptions
    Multiple non-preferred products and biosimilars (selected examples)
    Patient must have tried and failed to have an adequate response to the specified preferred agent or biosimilar listed for each product (see policy for product-specific comparators).
    Applies to new starts only; exceptions allowed for documented contraindication or intolerance. Specific J-codes and comparators are enumerated in the policy.
    StepRequired agent(s) in sequence (new starts)Applicable products / Notes
    Step 1
    Bevacizumab (Avastin)
    Step 1 applies to intravitreal anti-VEGF new starts; some agents require a Step 2 as described below (Byooviz, Lucentis, Susvimo).
    Drug / ProductRequired prior therapy (new starts)Notes / Exceptions
    Axtle (J9292) / Pemfexy (J9304) / Pemrydi RTU (J9324)
    Patient must have tried and failed to have an adequate response to pemetrexed (one of J9294, J9296, J9297, J9305, J9314, J9322, J9323), unless contraindicated or not tolerated.
    Applies to new starts only; does not apply for indications not shared with preferred pemetrexed agents.
    Drug / ProductRequired prior therapy (new starts)Notes / Exceptions
    Rituxan / Rituxan Hycela / Truxima
    Patient must have tried and failed to have an adequate response to Riabni or Ruxience.
    Applies to new starts only; does not apply when indication is not shared with Riabni or Ruxience.
    Drug / ProductRequired prior therapy (new starts)Notes / Exceptions
    (General entry for listed products)
    Patient must have tried and failed to have an adequate response to the specified preferred comparator listed in the policy.
    Applies to new starts only; see product-specific sections for precise comparators and documentation requirements.
    Drug / ProductRequired prior therapy (new starts)Notes / Exceptions
    Epoetin alfa alternatives (Epogen / Procrit alternatives)
    Patient must have tried and failed to have an adequate response to Retacrit.
    Applies to new starts only; does not apply when Epogen or Procrit is used for an indication not shared with Retacrit.
    Drug / ProductRequired prior therapy (new starts)Notes / Exceptions
    G-CSF non-preferred agents
    Patient must have tried and failed to have an adequate response to Zarxio.
    Applies to new starts only; exception when indication is not shared with Zarxio.
    Drug / ProductRequired prior therapy (new starts)Notes / Exceptions
    Infliximab biosimilars (Avsola / Inflectra / Renflexis)
    Patient must have tried and failed to have an adequate response to generic infliximab or Remicade.
    Applies to new starts only; does not apply when the biosimilar is used for an indication not shared with generic infliximab/Remicade.
    Drug / ProductRequired documentation (new starts)Notes / Exceptions
    Invega Hafyera
    Documentation of prior paliperidone palmitate treatment: at least 4 months of 1-month paliperidone palmitate OR at least one 3-month paliperidone palmitate injection.
    Required for approval of listed Invega Hafyera strengths on new starts only.
    Drug / ProductRequired prior therapy (new starts)Notes / Exceptions
    Intravitreal ranibizumab products (Cimerli / ranibizumab-eqrn) and other intravitreal anti-VEGF agents (Byooviz, Lucentis, Susvimo)
    Step 1: patient must have tried and failed bevacizumab (Avastin). For certain agents (Byooviz, Lucentis, Susvimo) Step 2 requires trial and failure of either Cimerli/ranibizumab-eqrn or aflibercept/brolucizumab/faricimab after bevacizumab.
    Applies to shared ophthalmic indications on new starts only; see policy for step sequencing details and exceptions for non-shared indications.
    Drug / ProductRequired prior therapy (new starts)Notes / Exceptions
    Axtle / Pemfexy / Pemrydi RTU
    Patient must have tried and failed to have an adequate response to pemetrexed (specified J-codes) unless contraindicated or not tolerated.
    Applies to new starts only; documentation of contraindication/intolerance accepted where applicable.
    Drug / ProductRequired prior therapy (new starts)Notes / Exceptions
    Rituxan / Rituxan Hycela / Truxima
    Patient must have tried and failed to have an adequate response to Riabni or Ruxience.
    Applies to new starts only.

    Site of Care and Billing

    Note

    Biosimilar and Comparator Requirements

    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note

    Definitions

    New starts
    DefinitionNew starts: cases in which the patient is initiating the listed drug; many criteria explicitly apply only to new starts and require prior trial and failure of specified comparator drugs.
    Typical implicationStep therapy and prior authorization rules frequently apply only to new starts; continuation patients may be exempt per policy language.
    DocumentationProviders must document prior trial and inadequate response, intolerance, or contraindication for new starts when required.
    Shared indication
    DefinitionShared indication: an indication common to both the requested drug and the preferred comparator; some step requirements do not apply when the requested product is used for an indication not shared with the comparator.
    Policy impactIf the requested drug is used for a non-shared indication, the step requirement may be waived per policy statements.
    Provider actionIndicate if the requested use is for an indication not shared with the preferred comparator when submitting prior authorization.
    new starts
    DefinitionNew starts (therapy initiations) are the scenarios where step therapy requirements apply; several entries explicitly limit requirements to new starts only.
    ScopeMany listed step requirements (examples include paliperidone palmitate, pemetrexed alternatives, bevacizumab sequencing) are applicable only to new therapy initiations.
    Submission noteFor new starts, documentation of prior trial and failure/intolerance/contraindication to specified preferred agents is required for approval.
    non-preferred denosumab biosimilar
    DefinitionNon-preferred denosumab biosimilar: a denosumab product not listed as preferred (e.g., Prolia/Xgeva alternatives) for which prior trial of specified preferred denosumab biosimilars is required before approval.
    Required prior agentsFor Prolia: trial and failure of Bildyos or Jubbonti; for Xgeva: trial and failure of Bilprevda or Wyost (applies to new starts).
    ExemptionRequirement does not apply if the non-preferred denosumab is used for an indication not shared with the preferred biosimilars.
    new starts
    DefinitionNew starts: patients initiating therapy with the listed non-preferred agent; many prior-authorization and step requirements apply specifically to these patients.
    ExampleNon-preferred pegfilgrastim biosimilars or Ryzneuta require prior trial and failure of Udenyca for new starts.
    Provider actionDocument prior trial of preferred product(s) when requesting a non-preferred agent for a new start.
    Levoleucovorin vs leucovorin
    ClarificationLevoleucovorin vs leucovorin: the levoleucovorin prior‑trial requirement for Khapzory does not apply when the patient is using levoleucovorin for indications not shared with leucovorin.
    Khapzory requirementKhapzory requires prior trial and failure of generic leucovorin for new starts unless the levoleucovorin exception applies.
    Provider actionIndicate use of levoleucovorin for a non-shared indication when submitting prior authorization to avoid unnecessary trial documentation.
    Non-preferred pegfilgrastim
    DefinitionNon-preferred pegfilgrastim: pegfilgrastim biosimilars or Ryzneuta that are not listed as preferred; prior trial of Udenyca is required for new starts.
    ExceptionRequirement does not apply when the non-preferred product is used for an indication not shared with the preferred pegfilgrastim product.
    DocumentationProvider must document prior trial and inadequate response to Udenyca for new-start requests of non-preferred pegfilgrastim products.
    new starts
    DefinitionNew starts: therapy initiations where step therapy requirements apply; many policy entries explicitly state the requirement is limited to new starts only.
    ImplicationClinicians should confirm whether a request is a new start when preparing prior authorization documentation, since many rules are new-start specific.
    DocumentationRecords should show trials of preferred agents and reasons for failure/intolerance/contraindication when applicable to new starts.

    Background

    Step therapy is a utilization management approach that requires patients to try preferred or lower‑cost medications first before coverage of alternative agents is approved. This policy lists specific Medicare Part B drugs and the required prior agent(s) for new therapy starts under Independent Health Medicare Advantage plans; many entries specify trial and inadequate response, intolerance, or documented contraindication to the preferred agent as the condition for approval.

    Applies to new starts only.

    Opdualag: Requires failure of Opdivo+Yervoy OR documented contraindication to Yervoy for new starts.

    Applies to new starts only.

    Abraxane: Non‑pancreatic/small bowel indications require failure of generic paclitaxel for new starts.

    Applies to new starts only.

    Pegfilgrastim biosimilars: Non‑preferred biosimilars/Ryzneuta require failure of Udenyca for new starts.

    Applies to new starts only.

    Pemetrexed alternatives: Axtle/Pemfexy/Pemrydi require failure of listed pemetrexed drugs (J-codes) unless contraindicated for new starts.

    Applies to new starts only.